IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Formulation And Evaluation Of Chlorzoxazone Tablet By Solid Disperssion Method.

Dr.Balkrishna Tiwari[1], Dr.Dipali Bolde[2], Ms. Snehal Bhingare[3], Ms.Sanika Bhagawat[4], Ms.Shreya Badagu[5]

[1]Professor, Department of Pharmaceutical Chemistry, Amepurva Forum Nirant Institute of Pharmacy, Solapur, India.

[2]Assistant Professor, Amepurva Forums Nirant Institute Of Pharmacy, Solapur, India.

[3]Student B.Pharm Final Year, Amepurva Forums Nirant Institute Of Pharmacy, Solapur, India.

[4]Student B.Pharm Final Year, Amepurva Forums Nirant Institute Of Pharmacy, Solapur, India.

[5]Student B.Pharm Final Year, Amepurva Forums Nirant Institute Of Pharmacy, Solapur, India.

Abstract: With a shorter half-life (1hour) and a dosage of three to four times per day, chlorzoxazone is a centrally acting muscle relaxant that is used to treat muscle spasm and the pain and discomfort that follows. The study's objective was to make and evaluate Chlorzoxazone tablet. The medication and the polymer matrix are the two main components of a solid dispersion. There are many different ways to make solid dispersions, including lyophilization, hot melt extrusion, melt agglomeration, fusion, kneading, melting, solvent evaporation, spray drying, co-grinding, and supercritical fluid (SCF) technological methods. Drugs that are poorly aqueously soluble have had their dissolving properties and bioavailability improved by a range of hydrophilic carriers. An attempt has been made to examine the various carriers utilized for solid dispersions and the thorough techniques of preparation in this review. Chlorzoxazone has a markedly reduced solubility and is a member of BCS class II. Due to its limited solubility, the medicine has a markedly low bioavailability since the liver's CYP2E1 enzyme uses the most of it for metabolism. The primary goal of the project is to create solid dispersions that will increase the drug's solubility. There is nothing steady or ever acceptable in this world. Nature naturally requires change in order to be adaptable. But the pharmaceutical industry is also seeing this shift. In the pharmaceutical industry, technological advancements also result in the creation of novel dosage forms. This results in the newer dose forms replacing the older ones. However, with some adjustments, this alternative is used for tablet dose forms. Furthermore, the availability of a wide range of evaluation characteristics gives these new tablet adaptations a precise demonstration concept.

Key Words: Solid Disperssion, Chlrzoxazone, Polymer, Solubility

1.Introduction:

Due to its easy manufacture, reduced volume, and accurate dosing, oral drug delivery is the most straightforward and effective method of administering medications. Compared to other forms of oral dosage forms, solid dosage forms offer a number of advantages. Consequently, the majority of newly developed novel chemical entities (NCEs) are intended to be used in solid dosage forms that, when administered orally, produce a repeatable and efficient in vivo plasma concentration. However, the formulation of poorly water-soluble drugs has long been a difficult problem for pharmaceutical chemists, and this problem

is only going to get worse because at least 40% of the NCE produced by drug discovery programs have water-soluble problems. One centrally acting muscle relaxant used to treat muscular spasms and the associated pain and discomfort is chlorzoxazone (5-chloro-2,3-dihydro-1,3-benzoxazol-2-one) Chlorzoxazone may work by preventing the inflow of calcium and potassium, which would cause muscular relaxation and neural inhibition. Patient compliance is reduced when the medication is administered three to four times a day and has a shorter half-life (1.lhour) [3, 4]. It is preferable to use a sustained-release formulation of chlorzoxazone to reduce the frequency of drug administration and to improve patient compliance.



Chlorzoxazone Structure

Solid dispersions have the following advantages over other methods of improving solubility: As particle size decreases, the rate of dissolution increases. Improvement in wettability confirmed by solid dispersions By creating solid dispersions, the degree of porosity in the particles rises. Solid dispersions change a drug's crystalline form into an amorphous one. To manufacture weakly soluble chemicals with dissolution-rate-limited absorption, one viable method is the solid dispersion approach. Since 1960, research into the use of solid dispersion technology in the formulation of medications with low water solubility has been ongoing. This methodology was easiest, most cost-effective, and most beneficial method for enhancing the bioavailability and solubility of poorly soluble medications, A solid dispersion is a collection of solid products made up of at least two distinct ingredients, usually a hydrophilic matrix and a hydrophobic medication.

2.Materials and methods:

2.1. Materials:

Chlorzoxazone (Amepurva Forums Nirant Institute of Pharmacy), Polymer Urea (Amepurva Forums Nirant Institute of Pharmacy), Mafanecium Sterate(Amepurva Forums Nirant Institute of Pharmacy), CMC (Amepurva Forums Nirant Institute of Pharmacy),HPMC (Amepurva Forums Nirant Institute of Pharmacy)

2.2 Method:

2.2.1. Hot Melt Extrution Method:

Incorporate Polymer into china Dish by continuous heating.

↓

Polymer maintain the temperature of of burner with polymer's melting Point

↓

incorporate Drug directly Into melt polymer

↓

remove china Dish from burner and kept into ice bath.then

"Collect the combination of Drug & Polymer & kept into Desiccator for 24 hours.

2.2.2. Formulation Table:

Batch	Drug	Polymer	Magnesium Sterate	CMC	HPMC
F1	0.5gm	0.5gm	0.075gm	0.1gm	0.1gm
F2	0.5gm	1gm	0.075gm	0.1gm	0.1gm
F3	0.5gm	1.5gm	0.075gm	0.1gm	0.1gm
F4	0.5gm	2gm	0.075gm	0.1gm	0.1gm

2.2.3. Evaluation Test:

2.2.3.1. Friability Test

A tablet's friability can be determined in a research center using a Rochefriabilator. The friabilator consists of a plastic chamber that rotates at 25 rpm, falling the tablets through a distance of six crawls. This process is repeated 100 times. The tablets are examined again. It is deemed sufficient to pack tablets that lose less than 0.5 to 1.0% of their weight. Figure No. 2 shows a friabilator. Uniformity of Drug Content Test of Weight Variety (U.S.P.) Weigh each of the 20 tablets separately. AscertainNormal weight and ponder about the unique tablet weight in relation to the norm. It is a tablet's propensity to powder, chip, or fragment, which can impact the tablet's elegant appearance, consumer acceptance, weight variance, or content consistency issues. One characteristic that is connected to the tablet's hardness is its friability. The Roche friabilator is a tool used to assess a tablet's resistance to abrasion during handling, shipping, and packaging. A tablet's friability can be assessed in a lab using a Roche friabilator. This consists of a plastic chamber that rotates at 25 rpm and drops the tablets into the friabilator six inches away. The chamber then rotates 100 times. They reweigh the tablets. Tablets that compress and lose less than 0.5 to 1.0% of their weight are deemed acceptable. A friability test can be conducted using the same 20 tablets as are used in the weight variation test. So here weight of 20 tablets is W1 = 6050mg = 6.05 gm

Now you have to put this 20 tablets in friabilator

Adjust the instrument at 100 rpm (i.e. = 25 rpm for 4 min)

final Weight of the 20 = W2 tablets = 5995 mg = 5.995 gm

Friability (% loss) = W1-W2/W1*100

= 6.05-5.995/6.05* 100 = 0.90%

so Friability is 0.90, it is not more than 1.0

2.2.3.2. Disintegration Test:

An official test is the disintegration test. The amount of time needed for the tablet to fragment, the A disintegration test simply calculates how long it takes for a batch of pills to break up into smaller pieces under specific circumstances. It is carried out in order to determine when a tablet will disintegrate. Controlled and sustained release pills are not subjected to disintegration testing. For the disintegration time test, The basket rack is set up in a 1-L beaker of water, and one tablet is put in each tube. Capacity of the vessel: 1 litter Fluid: either intestine or gastric simulated fluid. Motion up and down tablet is still 2.5 cm below the liquid's surface when moving upward and no closer than 2.5 cm when moving downhill from the beaker's bottom. The Indian Pharmacopoeia was used to establish the pills' disintegration time. Tablet disintegration equipment was used for the test. At 37 ± 0.2 °C, 900 milliliters of distilled water were utilized as a disintegrating medium. It was documented how long it took for every tablet to completely dissolve. Time required for disintegration of chlorzoxazone tablet is 20 min.

2.2.3.3. Hardness Test:

Hardness Test is the most important feature for assessing tablet in the study it was found that Tablet passed the test of tablet crushing strength or hardness both these brand have acceptable crushing strength of Between 5kKg/Cm2 to 10kg/Cm2 This test done from Pfizer Test machine. A crucial quality control test in the pharmaceutical sector, the hardness examination of tablets establishes their strength and endurance. Hardness is a crucial factor that influences how well tablets dissolve, disintegrate, and function overall. This is a synopsis of the hardness evaluation test, covering the tools and procedures used: 1. The objective of hardness testing to guarantee that tablets can tolerate mechanical strain while being made, packaged, and transported. to evaluate how well the tablet dissolves and releases the active pharmaceutical ingredient (API) into the body. to guarantee the tablets' ability to tolerate mechanical strain throughout production, packing, and shipping. to evaluate the tablet's capacity to deliver the active pharmaceutical ingredient (API) into the body through breakdown. Hardness testers such as Schleuniger, Strong-Cobb and Monsanto hardness testers. hardness of chlorzoxazone tablet is 7kg.

2.2.3.4. Thickness Test:

In the pharmaceutical sector, the thickness test of tablets is a crucial quality control method. It guarantees that tablets are produced with uniform dimensions, which can affect packaging, dosage consistency, and patient compliance in general. An outline of the thickness evaluation test's goals, procedures, and factors is provided below. Uniform Dosage Guarantees that every amount of active pharmaceutical ingredient (API) in the pill is accurate. Maintaining uniformity in tablet size and shape is essential for labeling and packing, and quality control helps achieve this. The tablet thickness was calculated using Vernier calipers. It is expressed as mm. The quality and uniformity of tablets are ensured by evaluating the results of thickness tests. the thickness of chlorzoxazone tablet is4.2mm.

2.2.3.5. Weight variation Test:

Twenty tablets were weighed separately, the average weight was determined, and the individual tablet weights were compared to the average in order to perform the weight variation test. After calculating the percentage weight deviation and comparing it to the IP limitations, the weight variation test was passed. A crucial assessment method used in the pharmaceutical sector to guarantee the consistency and quality of tablets is the weight variation method. It entails weighing each tablet separately and comparing the results to predetermined standards. This technique is crucial for preserving product quality and adhering to legal requirements since it helps guarantee that every tablet has the appropriate quantity of the active pharmaceutical ingredient (API). A vital quality control method, the weight variation test checks that tablet weights are within permissible bounds established by pharmacopoeial standards. By comparing the weight of each tablet to the average weight, this test verifies that the dose requirements are met. The weight variation test is essential for maintaining consistent dosage and regulatory compliance, which protects product quality by evaluating uniformity among tablets from a production batch.

2.2.3.6. Disslution Test:

A crucial quality control method for assessing the release of active pharmaceutical ingredients (APIs) from solid dosage forms, such tablets and capsules, is the dissolution test. This test aids in confirming that the drug's release is consistent with the therapeutic effect for which it was designed. Here is a summary of the main elements of the tablet assessment dissolution test: Dissolution Testing's Objective Assessing the rate and degree of the active ingredient's release into solution and availability for absorption is known as bioavailability. Quality Control: To guarantee uniformity among various tablet batches. Formulation Development: To support the creation and refinement of novel formulations. The purpose of this test is to ascertain whether the solid dosage given orally satisfies the dissolving requirements. The test is designed for tablets or capsules. To ascertain whether solid dosage forms given orally meet the dissolution requirements, This test is offered. dosage unit is defined in this chapter as one tablet, one capsule, or the amount indicated. (According to RP) Unless instructed otherwise, use Apparatus Every component of the equipment that could come into touch with the preparation being examined or the dissolving liquid is chemically inert and doesn't react or interfere with the preparation being examined.

RESULT:

FTIR Of Chlorzoxazone



Fig No:1 Systematic representation of FTIR of Chlorzoxazone Drug.

Wavenumber (cm-1	Possible Functional Group	Type of Vibration	Comments
3153.07	N-H/O-H stretch (possibly NH)	Stretching	Broad or sharp, indicative of amine or alcohol

3053.21	=C-H (Aromatic C-H)	Stretching	Typically aromatic or alkene C-H stretch
1772.75	C=O (Carbonyl group)	Stretching	Likely ester or anhydride due to high wavenumber
1618.93	C=C (Aromatic or alkene)	Stretching	Indicates presence of C=C bonds
1477.95	CH2/bending	Bending	Common in alkanes
1365.55	CH_3 bending	Bending	Methyl group presence
1298.45	C-N or C-0	Stretching	Could be amine or ether
1258.78	C-N/C-O	Stretching	Possibly ester or aromatic amine
1158.01	C-O-C (Ethers/Esters)	Stretching	Strong sharp peaks typical of C-O stretch
1104.92	C-O/C-N	Stretching	Indicative of alcohols, ethers, amines
1064.18	C-O/C-N	Stretching	similar as above
962.93	=C-H bending	Out-of-plane bending	often from alkenes.

Table 1: Interpretation of FTIR of Chlorzoxazone.

CONCLUSION:

The goal of the study was to improve the water solubility and drug release profile of nitrofurantoin by creating solid dispersions using the melt granulation process. FTIR measurements demonstrated that there is no interaction between the polymers and nitrofurantoin. Six batches of SD were made using melt granulation, which is utilized to create SD of nitrofurantoin with PEG 6000 and Poloxamer 188 at varying concentrations. The formulas' yield percentages ranged from 93.32% to 96.56%. The F2 and F5 batches showed the highest entrapment effectiveness, at 90.7% and 95.42%, respectively. The solid dispersion's SEM investigation revealed a reduction in crystallinity. The medication contained in the formulation was amorphous, according to DSC measurements. The shaking flask method was used to evaluate the solubility of pure Nitrofurantoin and its solid dispersion in distilled water. There was an increase in solubility. The F2 batch's in-vitro drug release was discovered to be 78.47%. It was determined that PEG 6000 and Poloxamer 188 were used in the melt granulation process to create the Nitrofurantoin Solid Dispersions. The F2 batch containing the polymer (PEG 6000) was deemed the optimal batch based on entrapment efficiency, solubility analysis, FTIR analysis, SEM, DSC, and other factors. Solid dispersion is shown to dissolve at higher rates than pure medication, which may be due to the drug's improved solubility. The evaluation results for pre-compression and post-compression fall within the acceptable range. The direct compression approach could be used to create optimized solid dispersions of nitrofurantoin into tablets. When compared to pure medication tablets, the optimized formulation demonstrated quicker drug release. The statistics clearly show that a larger concentration of polymers results in a faster release of the medication. Therefore, one of the most promising methods for increasing the solubility of drugs that are not very soluble in water is solid dispersion. The results of the above study show that the research work was satisfactory to improve the aqueous solubility and release profile of Nitrofurantoin.

REFERENCES:

1. Sweetman SC. Martindale: The Complete Drug Reference, 37th ed. London: Pharmaceutical Press; 32-33, 2011.
2. Mofizur Rahman, Md., Sumon, Roy., Sreedam Chandra Das., J. Pharm. Sci. & Res. 2011, 3,930-938
3. Clement Jackson, Musiliu Adedokun., Int J Pharm Pharm Sci. 2011, 3 (5), 64-67.

4. 4El-Nabarawi MA, El-Miligi MF, Khalil IA. Optimization of class II BCS drug using solid dispersion technique. International Journal of Pharmacy and Pharmaceutical Sciences. 2012;4(5):554-71.
5. SJadhav YL, Parashar B, Ostwal PP, Jain MS. Solid dispersion: Solubility enhancement for poorly water soluble drug. Research Journal of Pharmacy and Technology. 2012; 5(2):190-7.
6. Lipinski CA, Lombardo F, Dominyl BW and Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997; 23:3-25.
7. Streubel A. et al. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr. Opin. Pharmacologic. 2006; 6: 501 -508.
8. Stephanie Bosselmann, III ROW. Route-specific challenges in the delivery of poorly water-soluble drugs. In: Robert O. Williams III, Alan B. Watts, Miller DA, editors. Formulating poorly water soluble drugs. USA: Springer. American Association of Pharmaceutical Scientists. 2012: 1-26.
9. Morgen M, Bloom C, Beyerinck R, Bello A, Song W, Wilkinson K. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high- permeability drug. Pharm Res. 2012; 29(2): 427-440.
10. B. R. Ahire, B. R. Rane, S. R. Bakliwal and S. P. Pawar. Solubility Enhancement of Poorly Water Soluble Drug by Solid Dispersion Techniques. Int. J. PharmTech Res. 2010; 2: 2007-2015.
11. Sanjoy Kumar Das, SudiptaRoy, Yuvaraja Kalimuthu. Solid Dispersions: An Approach to Enhance the Bioavailability of Poorly Water-Soluble Drugs, International Journal of Pharmacology and Pharmaceutical Technology; 2011; 1:37-46.
12. Shah TJ, Amin AF, Parikh JR, Parikh RH. Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug. AAPS PharmSciTech. 2007;8(2):Article 29.
13. F. Usui, K. Maeda, A. Kusai, M. Ikeda, K. Nishimura and K. Yamamoto. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int. J. Pharm. 1997; 1997: 59-66.
14. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017-25.
15. ATM S. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent breakthroughs. J Pharm Sci. 1999;88: 1058-66.
16. Agrawal S, Pancholi SS, Jain NK, Agrawal GP. Hydrotropic solubilization of nimesulide for parenteral administration. Int J Pharm. 2004;274(1-2):149-55.